CoChat
Sign Up
Cited by 348Retinal Diseases and TreatmentsComplement system in diseasesOcular Diseases and Behçet’s Syndrome

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Complement Factor H Polymorphism, Complement Activators, and Risk of Age-Related Macular Degeneration

Open access
Despriet, Dominiek D. G., Klaver, Caroline C. W., Witteman, Jacqueline C. M., Bergen, Arthur A. B., Kardys, Isabella, de Maat, Moniek P. M., Boekhoorn, Sharmila S., Vingerling, Johannes R., Hofman, Albert, Oostra, Ben A., Uitterlinden, André G., Stijnen, Theo, van Duijn, Cornelia M., de Jong, Paulus T. V. M.·2006·JAMA
DOI 10.1001/jama.296.3.301
Open this paper in CoChat — free account

Abstract

CONTEXT: The evidence that inflammation is an important pathway in age-related macular degeneration (AMD) is growing. Recent case-control studies demonstrated an association between the complement factor H (CFH) gene, a regulator of complement, and AMD. OBJECTIVES: To assess the associations between the CFH gene and AMD in the general population and to investigate the modifying effect of smoking, serum inflammatory markers, and genetic variation of C-reactive protein (CRP). DESIGN, SETTING, AND PARTICIPANTS: Population-based, prospective cohort study of individuals aged 55 years or older (enrollment between March 20, 1990, and July 31, 1993, and 3 follow-up examinations that were performed between September 1, 1993, and December 31, 2004) in Rotterdam, the Netherlands. The CFH Y402H polymorphism was determined in a total of 5681 individuals. Information on smoking, erythrocyte sedimentation rate, CRP serum levels, and haplotypes of the CRP gene were assessed at baseline. MAIN OUTCOME MEASURES: All severity stages of prevalent and incident AMD, graded according to the international classification and grading system for AMD. RESULTS: The frequency of CFH Y402H was 36.2% (4116/11,362 alleles). At baseline, there were 2062 persons (36.3%) with any type of AMD (prevalent cases), including 78 (1.4%) with late AMD (stage 4). During follow-up (mean, 8 years; median, 10 years), 1649 (35.5%) of 4642 participants progressed to a higher stage of AMD (incident cases), including 93 (5.6%) who developed late AMD. The odds ratio (OR) of AMD increased in an allele-dose manner with 2.00 (95% confidence interval [CI], 1.56-2.55) for stage 2 AMD, 4.58 (95% CI, 2.82-7.44) for stage 3 AMD, and 11.02 (95% CI, 6.82-11.81) for stage 4 (late, vision threatening) AMD for homozygous persons. Cumulative risks calculated by Kaplan-Meier analysis of late AMD by age 95 years were 48.3% for homozygotes, 42.6% for heterozygotes, and 21.9% for noncarriers. The population-attributable risk for CFH Y402H was 54.0%. Elevated erythrocyte sedimentation rates further increased the OR to 20.2 (95% CI, 9.5-43.0), elevated serum CRP levels to 27.7 (95% CI, 10.7-72.0), and smoking to 34.0 (95% CI, 13.0-88.6) for homozygotes compared with noncarriers without these determinants. The CRP haplotypes conferring high levels of CRP significantly increased the effect of CFH Y402H (P<.01). CONCLUSIONS: The CFH Y402H polymorphism may account for a substantial proportion of AMD in individuals similar to those in the Rotterdam Study and may confer particular risk in the presence of environmental and genetic stimulators of the complement cascade.

Overview

Integrity signals

Registry

Crossref · 10.1001/jama.296.3.301

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 44 references

Cited by

Sorted by citations

Items 301–347 of 347

Related

See all

Metadata

Authors
Despriet, D. D. G., Klaver, C. C. W., Witteman, J. C. M., Bergen, A. A. B., Kardys, I., de Maat, M. P. M., Boekhoorn, S. S., Vingerling, J. R., Hofman, A., Oostra, B. A., Uitterlinden, A. G., Stijnen, T., van Duijn, C. M., & de Jong, P. T. V. M.
Affiliations
  • Erasmus MC (NL)
  • Netherlands Institute for Neuroscience (NL)
  • Amsterdam Neuroscience (NL)
ORCID
Venue
JAMA
Publisher
American Medical Association (AMA)
Published
2006-07-19
Volume
296
Issue
3
Pages
301
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
DOI
10.1001/jama.296.3.301
OpenAlex
W2107143742
Cited by
348
References
44
Citations by year
2026: 4 · 2025: 6 · 2024: 8 · 2023: 9 · 2022: 2 · 2021: 8 · 2020: 10 · 2019: 11 · 2018: 8 · 2017: 8 · 2016: 7 · 2015: 21 · 2014: 17 · 2013: 28 · 2012: 24
FWCI
36.22
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • JAMA (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • KNAW research portal (Royal Academy of Art and Sciences (KNAW)) (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion)
Funders
Erasmus Medisch Centrum
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
age-related macular degeneration, complement factor H, CFH Y402H polymorphism, complement system, genetic susceptibility, smoking, C-reactive protein, serum inflammatory markers, erythrocyte sedimentation rate, inflammation, AMD progression, late AMD, genetic risk factors, Rotterdam Study, older adults, gene-environment interaction
MeSH terms
Aged, Aged, 80 and over, Blood Sedimentation, C-Reactive Protein, Complement Pathway, Alternative, Female, Haplotypes, Humans, Leukocyte Count, Macular Degeneration, Male, Middle Aged, Polymorphism, Genetic, Prospective Studies, Risk Factors, Smoking, Cohort Studies, Complement Factor H, Inflammation Mediators

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review